Nisa Investment Advisors LLC Has $27,000 Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Nisa Investment Advisors LLC boosted its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 417.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,827 shares of the biotechnology company’s stock after buying an additional 2,281 shares during the period. Nisa Investment Advisors LLC’s holdings in Enanta Pharmaceuticals were worth $27,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Diversified Trust Co acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $159,000. Walleye Capital LLC increased its holdings in shares of Enanta Pharmaceuticals by 342.8% during the 3rd quarter. Walleye Capital LLC now owns 119,364 shares of the biotechnology company’s stock valued at $1,333,000 after acquiring an additional 92,410 shares during the last quarter. Krensavage Asset Management LLC raised its stake in shares of Enanta Pharmaceuticals by 6.9% in the 3rd quarter. Krensavage Asset Management LLC now owns 735,103 shares of the biotechnology company’s stock valued at $8,211,000 after acquiring an additional 47,490 shares in the last quarter. Laurion Capital Management LP acquired a new stake in Enanta Pharmaceuticals in the 3rd quarter worth approximately $126,000. Finally, Armistice Capital LLC lifted its stake in shares of Enanta Pharmaceuticals by 3.1% in the third quarter. Armistice Capital LLC now owns 2,100,000 shares of the biotechnology company’s stock worth $23,457,000 after buying an additional 64,000 shares during the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ENTA shares. JPMorgan Chase & Co. cut their price objective on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th. StockNews.com cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, April 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.33.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $13.44 on Tuesday. The company has a market capitalization of $284.39 million, a price-to-earnings ratio of -2.05 and a beta of 0.47. The company has a 50-day moving average of $14.84 and a 200-day moving average of $11.78. Enanta Pharmaceuticals, Inc. has a 52 week low of $8.08 and a 52 week high of $37.75.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. Sell-side analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.9 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.